Vamshi Krishna Rapalli

Vamshi Krishna Rapalli

Auto-generated profile, based on publicly available information

Vamshi Krishna Rapalli

Birla Institute of Technology and Science

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
TWTejashree Waghule
Tejashree Waghule
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
SGSrividya Gorantla
Srividya Gorantla
RSRanendra Narayan Saha
Ranendra Narayan Saha
SDSunil Dubey
Sunil Dubey
GSGautam Singhvi
Gautam Singhvi
Background: Skin diseases affect all the age groups of people and have an impact on patients’ physical, mental, and emotional status. Conventional topical preparation is limited with its efficacy due to low permeation, frequent application, and poor adherence to the therapy for prolong time. Objective: The objective of this review article is to address the emerging trends of nanotechnology derived lipidic carrier systems for an effective treatment for skin disorders. Methodology: Various research and review articles from reputed international journals were referred and compiled. Results and Discussion: opical drug delivery systems were found to be more effective than oral and parenteral drug delivery systems for treating skin diseases due to targeted localized applications with reduced side effects. Lipid-based nanoparticles have been found to have the potential in treating skin diseases due to the biocompatibility and the versatility of the lipids. Nanostructured lipid carriers (NLCs) have gained much attention in treating skin diseases due to improved stability of the drugs, enhanced skin permeation, retention, and better therapeutic efficacy. The review summarizes the NLCs characteristics and their application for topical delivery of various therapeutics in skin disorders. NLCs have shown great potential in effective drug delivery for the treatment of psoriasis, dermatitis, bacterial infections, and skin cancer. Its cosmetic application has opened a new area for skincare. Furthermore, safety and clinical status revealed its future commercial acceptability. Conclusion: NLCs have been found as effective lipid nanocarriers for the delivery of topical therapeutics.

1 October 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
SSSwati Sharma
Swati Sharma
ARAniruddha Roy
Aniruddha Roy
GSGautam Singhvi
Gautam Singhvi

10 December 2020 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
GSGautam Singhvi
Gautam Singhvi
Skin is the outermost largest organ in the body. It protects the body from physical, chemical, and microbial assaults and also prevents water loss from the body. The skin comprises three layers i.e...

2 December 2021 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
AMArisha Mahmood
Arisha Mahmood
TWTejashree Waghule
Tejashree Waghule
SGSrividya Gorantla
Srividya Gorantla
SDSunil Dubey
Sunil Dubey
GSGautam Singhvi
Gautam Singhvi
Investigating the transportation of a drug molecule through various layers of skin and determining the amount of drug retention in skin layers is of prime importance in transdermal and topical drug...

28 October 2020 in Liquid Crystals
Verified
Journal Article
Closed access
TWTejashree Waghule
Tejashree Waghule
SPShalini Patil
Shalini Patil
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
VGVishal Girdhar
Vishal Girdhar
SGSrividya Gorantla
Srividya Gorantla
GSGautam Singhvi
Gautam Singhvi

29 April 2020 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PDF file
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
SGSrividya Gorantla
Srividya Gorantla
TWTejashree Waghule
Tejashree Waghule
AMArisha Mahmood
Arisha Mahmood
PSPrem Prakash Singh
Prem Prakash Singh
GSGautam Singhvi
Gautam Singhvi
Age-related Macular Degeneration (AMD) is one of the common diseases affecting the posterior part of the eye, of a large population above 45 years old. Anti-Vascular Endothelial Growth Factor- A (Anti-VEGF-A) agents have been considered and approved as therapeutic agents for the treatment of AMD. Due to the large molecular weight and poor permeability through various eye membranes, VEGF-A inhibitors are given through an intravitreal injection, even though the delivery of small therapeutic molecules by topical application to the posterior part of the eye exhibits challenges in the treatment. To overcome these limitations, nanocarrier based delivery systems have been utilized to a large extent for the delivery of therapeutics. Nanocarriers system offers prodigious benefits for the delivery of therapeutics to the posterior part of the eye in both invasive and non-invasive techniques. The nano size can improve the permeation of therapeutic agent across the biological membranes. They provide protection from enzymes present at the site, targeted delivery or binding with the disease site and extend the release of therapeutic agents with prolonged retention. This leads to improved therapeutic efficacy, patient compliance, and cost effectiveness of therapy with minimum dose associated side-effects. This review has summarized various nanocarriers explored for the treatment of AMD and challenges in translation.